Pharma exports expected to double to $65 billion by 2030: Report

India's pharmaceutical exports are set to reach USD 65 billion by 2030 and USD 350 billion by 2047, placing India among the top five global exporters by diversifying its product range. The report highlights the need for innovation, quality focus, and collaboration between the government and private sector to achieve this growth, emphasizing specialty generics and biosimilars.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/FKca3Pn
via IFTTT

Read More

What are nutraceuticals and why are they gaining popularity in India

Nutraceuticals in India are gaining popularity due to rising health awareness, an increase in lifestyle diseases, and a shift toward natural products. The market is expected to grow significantly, driven by government initiatives, increased disposable incomes, and the expansion of online retail models.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/eywsiWZ
via IFTTT

Read More

Alkem Labs acquires two companies specialising in skin care, medtech to bolster domestic business

Alkem Laboratories has announced two strategic acquisitions totaling Rs 287 crores to strengthen its domestic market presence. The company will acquire Adroit Biomed for Rs 140 crore and Bombay Ortho Industries for Rs 147 crore. These acquisitions will diversify Alkem's portfolio and meet growing market demands.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lqh5xjt
via IFTTT

Read More

IHH Healthcare seeks damages of upto Rs 10,930 cr from Daiichi Sankyo for obstructing open offer for Fortis

IHH Healthcare is seeking up to Rs 10,930 crore in damages from Daiichi Sankyo for allegedly obstructing NTK's acquisition of Fortis Healthcare. IHH announced that NTK has submitted an additional claim with an expert report to quantify the damages. The dispute stems from a 2018 open offer block by Daiichi's contempt plea against Fortis founders.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/f2QU5Bg
via IFTTT

Read More

Dr Reddy's unit ties up with Shanghai Henlius Biotech

Dr Reddy's Laboratories has partnered with Shanghai Henlius Biotech to develop and commercialize HLX15, a biosimilar to the cancer drug Darzalex. Henlius will manage development and manufacturing, receiving up to $131.6 million. Dr Reddy's gains exclusive rights to market the drug in the US and Europe.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0IXQqVc
via IFTTT

Read More

GBS patient treated in Gurugram, cases rise in Pune

Healthcare authorities are closely monitoring the outbreak of Guillain-Barre Syndrome (GBS) in Pune as cases rise to 158, with five deaths suspected in Maharashtra. Doctors report instances of muscle weakness and dysfunction, primarily affecting the younger population, and are coordinating efforts with the Centre to control the spread.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/zIqmGZQ
via IFTTT

Read More

ICMR initiates process of vaccine against avian influenza

The ICMR has launched efforts to develop a human vaccine against the highly-pathogenic avian influenza H5N1. This virus poses a significant public health risk due to its high mortality rate and potential to cause global pandemic. Recent outbreaks highlight the urgency of vaccine development for better preparedness.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8vREa9O
via IFTTT

Read More